AbCellera Biologics Inc.
http://www.abcellera.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AbCellera Biologics Inc.
Lessons In Leadership And Biotech Growth From Rallybio CEO Martin Mackay
Veteran pharma leader Martin Mackay, CEO of Rallybio, recently spoke with In Vivo about building a new company on the cusp of retirement, what drives him, how he leads and what he is excited about in the company’s pipeline.
Deal Watch: Vertex Calls On CRISPR Yet Again, Now To Collaborate On Type 1 Diabetes
Vertex and CRISPR look beyond beta thalassemia and sickle cell disease. Also, Bicycle gets $50m up front in Novartis deal, Regeneron commits $75m initially under a Treg collaboration with Sonoma, and Jounce gets a better deal from Concentra to wave off Redx merger.
Deal Watch: Merck KGaA Teams Up With Mersana On STING Agonist ADCs
Mersana signs its third ADC partnership with big pharmas for the year with Merck agreement. Lilly expands its RNA editing partnership with ProQR, which now has the potential to earn an additional $2.5bn. Novartis continues its divestment efforts in deals with Harrow, Erasca.
Generate Biomedicines Picks First Targets To Test Its AI-Based Drug Discovery Revolution
Built with an audacious goal to use AI to unlock the secrets of protein structure and function, Generate Biomedicines believes it is now on the cusp of a drug discovery revolution.
Company Information
- Industry
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Digital Health
- Artificial Intelligence
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
-
Drug Discovery Technologies
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- TetraGenetics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice